miRNA therapeutics in cardiovascular diseases: promises and problems

被引:77
|
作者
Nouraee, Nazila [1 ]
Mowla, Seyed J. [1 ]
机构
[1] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
来源
FRONTIERS IN GENETICS | 2015年 / 6卷
关键词
ACUTE MYOCARDIAL-INFARCTION; CIRCULATING MICRORNAS; ATRIAL-FIBRILLATION; CARDIAC FIBROSIS; HEART-FAILURE; EXOSOMES; BIOMARKER; BIOGENESIS; DIAGNOSIS; CANCER;
D O I
10.3389/fgene.2015.00232
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
microRNAs (miRNAs) are a novel class of non-coding RNAs which found their way into the clinic due to their fundamental roles in cellular processes such as differentiation, proliferation, and apoptosis. Recently, miRNAs have been known as micromodulators in cellular communications being involved in cell signaling and microenvironment remodeling. In this review, we will focus on the role of miRNAs in cardiovascular diseases (CVDs) and their reliability as diagnostic and therapeutic biomarkers in these conditions. CVDs comprise a variety of blood vessels and heart disorders with a high rate of morbidity and mortality worldwide. This necessitates introduction of novel molecular biomarkers for early detection, prevention, or treatment of these diseases. miRNAs, due to their stability, tissue-specific expression pattern and secretion to the corresponding body fluids, are attractive targets for cardiovascular-associated therapeutics. Explaining the challenges ahead of miRNA-based therapies, we will discuss the exosomes as delivery packages for miRNA drugs and promising novel strategies for the future of miRNA-based therapeutics. These approaches provide insights to the future of personalized medicine for the treatment of CVDs.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
    Nada Bejar
    Trinh T. Tat
    Daniel L. Kiss
    Current Atherosclerosis Reports, 2022, 24 : 307 - 321
  • [22] Transplantation of Endothelial Progenitor Cells as Therapeutics for Cardiovascular Diseases
    Hung, Huey-Shan
    Shyu, Woei-Cherng
    Tsai, Chang-Hai
    Hsu, Shan-hui
    Lin, Shinn-Zong
    CELL TRANSPLANTATION, 2009, 18 (09) : 1003 - 1012
  • [23] Ischemic Microenvironment-Responsive Therapeutics for Cardiovascular Diseases
    Li, Xi
    Zhang, Yabing
    Ren, Xiangyi
    Wang, Yan
    Chen, Dongxu
    Li, Qian
    Huo, Minfeng
    Shi, Jianlin
    ADVANCED MATERIALS, 2021, 33 (52)
  • [24] Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
    Ji, Eunhye
    Lee, Sahmin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [25] Multifunctional role of nanoparticles for the diagnosis and therapeutics of cardiovascular diseases
    Arshad, Ihtesham
    Kanwal, Ayesha
    Zafar, Imran
    Unar, Ahsanullah
    Mouada, Hanane
    Razia, Iashia Tur
    Arif, Safina
    Ahsan, Muhammad
    Kamal, Mohammad Amjad
    Rashid, Summya
    Khan, Khalid Ali
    Sharma, Rohit
    ENVIRONMENTAL RESEARCH, 2024, 242
  • [26] Small Interfering RNAs and RNA Therapeutics in Cardiovascular Diseases
    Bansal, Parveen
    Arora, Malika
    NON-CODING RNAS IN CARDIOVASCULAR DISEASES, 2020, 1229 : 369 - 381
  • [28] Editorial: Highlights for Cardiovascular Therapeutics in 2021 - Trained Immunity, Immunometabolism, Gender Differences of Cardiovascular Diseases, and Novel Targets of Cardiovascular Therapeutics
    Yang, William Y.
    Nguyen, Bonnie
    Wu, Sheng
    Yu, Jun
    Wang, Hong
    Yang, Xiaofeng
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [29] Indian herbal medicines in the treatment of liver diseases: problems and promises
    Girish, Chandrashekaran
    Pradhan, Suresh Chandra
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 (02) : 180 - 189
  • [30] Progress and problems in the biology, diagnostics, and therapeutics of prion diseases
    Aguzzi, A
    Heikenwalder, M
    Miele, G
    JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02): : 153 - 160